Business
Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference
LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to
About this update from Equillium, Inc.
[{"type":"text","content":" LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will host investor meetings at the Wells Fargo Healthcare Conference, and present and host meetings at the H.C. Wainwright 25th Annual Global Investor Conference.\n\n\nManagement will provide an overview of the Company’s multi-cytokine inhibitor platform focused on EQ101 for the treatment of alopecia areata and EQ102 for the treatment of celiac disease, as well as the ongoing development of itolizumab in partnership with Ono Pharmaceutical, and upcoming milestones. Management will be available for one-on-one meetings during both conferences.\n\n\n\n\nConference:\n\n\n\n\n\n \n\nWells Fargo Healthcare Conference\n\n\n\n\n\n\n\n\nLocation:\n\n\n\n\n\n \n\nEncore Boston Harbor\n\n\n\n\n\n\n\n\nDates:\n\n\n\n\n\n \n\nWednesday, September 6 – Friday, September 8\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n \n\n \n\n\n\n\n\n\n\n\nConference:\n\n\n\n\n\n \n\nH.C. Wainwright, 25th Annual Global Investor Conference\n\n\n\n\n\n\n\n\nLocation:\n\n\n\n\n\n \n\nLotte New York Palace Hotel\n\n\n\n\n\n\n\n\nPresentation:\n\n\n\n\n\n \n\nTuesday, September 12, 7:30 am Pacific Time | 10:30 am Eastern Time\n\n\n\n\n\n\n\nWebcast access for the H.C. Wainwright conference will be available on the Events & Presentations page under the Investor Relations tab on the Company’s website. An archived replay of the presentation at the H.C. Wainwright conference will be available for 90 days.\n\n\nAbout Equillium\n\n\nEquillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of the following novel first-in-class immunomodulatory assets targeting immuno-inflammatory pathways. EQ101: a tri-specific cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15; currently under evaluation in a Phase 2 proof-of-concept clinical study of patients with alopecia areata. EQ102: a bi-specific cytokine inhibitor that selectively targets IL-15 and IL-21; currently under evaluation in a Phase 1 first-in-human clinical study to include...